PSTI - Pluristem Therapeutics Inc.
| Previous Close | 0.5640 |
| Open | 0.5616 |
| Bid | 0.5583 x 4000 |
| Ask | 0.7100 x 1300 |
| Day's Range | 0.5608 - 0.5800 |
| 52 Week Range | 0.5000 - 1.3800 |
| Volume | 155,295 |
| Avg. Volume | 633,601 |
| Market Cap | 86.143M |
| Beta (3Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3190 |
| Earnings Date | Feb 13, 2019 - Feb 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- GlobeNewswire•10 hours ago
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
“I am proud and pleased in successfully completing the transition period and the appointment of Yaky as Pluristem’s sole CEO,” said Zami Aberman. “As Executive Chairman I will continue to take an active role in shaping Pluristem’s corporate development and business strategy as we are advancing towards completion of our phase III studies and targeting our marketing phase.
- GlobeNewswire•7 days ago
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
This serum-free media formulation was developed using Pluristem’s deep understanding in cell therapy industrial scale production standards, and the quality methods designed to support implementation in Phase III development and marketing. Achieving this significant technological challenge enables Pluristem large-scale, highly consistent production with operational independency from third-party suppliers for standard serum, an expensive and quantity limited product. PLX-R18 is the first product that Pluristem intends to manufacture using the serum-free media.
- Simply Wall St.•10 days ago
Pluristem Therapeutics Inc. (NASDAQ:PSTI): Are Analysts Optimistic?
Pluristem Therapeutics Inc.'s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem...
- GlobeNewswire•last month
Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
The pivotal study is also designed to measure long-term outcomes and collect parameters to assess the potential economic benefit of this kind of treatment. Additionally, an invited commentary that also appears in EJVES lends strong support for the study’s design and potential impact.
- GlobeNewswire•2 months ago
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional patent application titled “Methods and Compositions for Producing Cannabinoids,” which covers the use of Pluristem’s state-of-the-art, proprietary 3-D cell culturing technology for the potential manufacturing of cannabinoid-producing cells.
- GlobeNewswire•2 months ago
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant milestone in its ongoing development of PLX-PAD for the treatment of critical limb ischemia (CLI). The company has met its enrollment timelines relating to its Phase III pivotal study in CLI sooner than expected, and has successfully enrolled over 50% of the study’s patients, which allows for an interim analysis of efficacy after a one-year follow-up period under the European Medicine Agency’s (EMA) Adaptive Pathways pilot project, which PLX-PAD was selected for. The interim analysis, if positive, could support an application for conditional marketing approval, which could accelerate the approval and commercial availability of PLX-PAD in the Europe.
- Simply Wall St.•2 months ago
Does The Pluristem Therapeutics Inc. (NASDAQ:PSTI) Share Price Tend To Follow The Market?
Anyone researching Pluristem Therapeutics Inc. (NASDAQ:PSTI) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of vol...
- GlobeNewswire•2 months ago
Pluristem Therapeutics Issues Shareholder Update
Recent financing provides funding through multiple potentially value-creating milestonesProviding short and mid-term milestones, targeting marketing and significant contracts.
- GlobeNewswire•3 months ago
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today the pricing of an underwritten public offering of 27,142,858 shares of its common stock and warrants to purchase up to 27,142,858 shares of its common stock with an exercise price of $0.70 per share at a public offering price of $0.70 per share and accompanying warrant. The warrants in the underwritten public offering have a term of five years and are exercisable immediately upon issuance. Pluristem also announced the pricing of a concurrent registered direct offering of 1,428,571 shares of its common stock at a price of $0.70 per share.
- Benzinga•3 months ago
The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 3) Denali Therapeutics Inc (NASDAQ: DNLI ) GALAPAGOS NV/S ...
- GlobeNewswire•3 months ago
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock
Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering and shares of its common stock in a concurrent registered direct offering. All of the shares and warrants in the underwritten public offering, and the shares in the concurrent registered direct offering, are to be sold by Pluristem. Pluristem intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrants offered in the public offering at the public offering price, less the underwriting discounts and commissions.
- GlobeNewswire•3 months ago
Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled the second cohort of six patients in its ongoing Phase I clinical study evaluating PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), and has received Data and Safety Monitoring Board (DSMB) approval to continue to the final cohort of the study. “We are highly encouraged by the findings from the first two cohorts in this study, and we are pleased to receive DSMB approval to continue with the study as planned, as we look to efficiently advance PLX-R18 through clinical development,” commented Zami Aberman, Chairman and Co-Chief Executive Officer of Pluristem.
- Simply Wall St.•4 months ago
Is Pluristem Therapeutics Inc.’s (NASDAQ:PSTI) Balance Sheet A Threat To Its Future?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Pluristem Therapeutics Inc. (NASDAQ:PSTI), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
- GlobeNewswire•4 months ago
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced a collaboration between the company and NASA’s Ames Research Center to evaluate the potential of Pluristem’s PLX cell therapies in preventing and treating medical conditions caused during space missions. Dr. Ruth Globus of NASA’s Ames Research Center, in California’s Silicon Valley, has been awarded a 2019 NASA Ames Research Innovation Award (ARIA) for the collaboration with Pluristem.
- Zacks•4 months ago
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Pluristem Therapeutics Inc. (PSTI) has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire•4 months ago
RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics
Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, today announced that the large-scale research initiative, RESTORE, of which Pluristem is a member, is nominated to be one of two finalists competing to be awarded up to €1 billion over the next 10 years by the EC for the development and advancement of transformative therapeutics. As a member of the RESTORE consortium, if RESTORE wins the award, Pluristem could receive a portion of the award, the amount of which is not yet determinable.
- Associated Press•5 months ago
Pluristem: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Haifa, Israel-based company said it had a loss of 7 cents. The biotechnology company posted revenue of $50,000 in the period. In the final minutes of trading on Wednesday, the ...
- Simply Wall St.•5 months ago
Read This Before Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
- GlobeNewswire•5 months ago
Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported the receipt of a joint grant awarded by the Israeli Ministry of Defense and the Israel Innovation Authority for the development of the company’s PLX cells for the treatment of burn injuries. This project entails collaboration between the Company, the Israeli Defense Forces (IDF) medical corps and professionals who specialize in burn injuries from Israeli hospitals.
- GlobeNewswire•5 months ago
Pluristem Therapeutics Reports Successful Case Study in Treatment of Buerger’s Disease Patient
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative-medicine company developing novel placenta-based cell therapy products, today reported a successful one-year follow up of a compassionate use treatment in a Buerger’s disease patient treated with Pluristem’s PLX-PAD. The thirty-six years old patient, who was diagnosed with Buerger’s disease approximately four years ago, displayed painful, non-healing ulcers on his foot.
- GlobeNewswire•6 months ago
Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced it has concluded a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the ongoing development of PLX-R18 for the treatment of Acute Radiation Syndrome (ARS). The FDA provided Pluristem with feedback on the progress and data collected on PLX-R18 to date and gave guidance towards advancing the development of PLX-R18 with respect to the treatment of ARS.
- GlobeNewswire•6 months ago
Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the Key Opinion Leader (KOL) breakfast meeting on peripheral artery disease (PAD) that the Company hosted on Friday, December 14 in New York. The meeting focused on the current treatment landscape, unmet medical need, economic impact and potential market opportunities for treating patients with PAD, a serious but common circulatory problem characterize by a blockage of the arteries and reduced blood flow to the limbs.
- GlobeNewswire•6 months ago
Reminder- Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease Tomorrow
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, will host a Key Opinion Leader (KOL) meeting on Peripheral Artery Disease (PAD) tomorrow, December 14, 2018 at 8am-9:30am EST, in New York City. The meeting will feature presentations by KOLs John Lantis, MD, Vice Chairman of the Department of Surgery and Chief of Vascular and Endovascular Surgery at Mount Sinai West, and Mary L. Yost, MBA, Co-Founder of The Sage Group, who will discuss the current treatment landscape and unmet medical needs, the economic impact, and potential market opportunities for treating patients with PAD.
- GlobeNewswire•7 months ago
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has entered into a license agreement with a subsidiary of Chart Industries, Inc. regarding Pluristem’s thawing device for cell-based therapies. Pluristem’s point-of-care thawing device technology is designed to allow for the precise and automated thawing of cells in a controlled and monitored environment, and is expected to result in the highest levels of cell viability and quality. The technology includes many advanced unique proprietary features which were designed to result in the leading thawing devices on the market.
- GlobeNewswire•7 months ago
Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented data from the first cohort of patients in its ongoing Phase I clinical trial of PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT) at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, which is being held December 1-4 in San Diego.
